MannKind Corporation (NASDAQ: MNKD)
MannKind Corporation has been seeing a bit of a change in tides as of late. While the company struggled to get Afrezza sales rolling in the beginning, things seem to be going in the right direction as CEO Michael Castagna leads the charge. Today, the company announced that it would be giving multiple presentations as well, which will likely provide yet another boost following yesterday’s 9%+ gains. Today, we’ll talk about the presentations that are coming down the line, why now is the time to start being excited about MNKD, and what we’ll be watching for ahead.
MNKD To Give 2 Presentations
As mentioned above, MannKind Corporation has a couple of presentations coming down the line. In a press release published this morning, the company, which is focused on developing therapeutic products to treat diabetes and other conditions, informed investors of these presentations. Here are the details:
- September 11th – On September 11th at 9:35 am ET, MNKD will be giving a presentation at the Rodman & Renshaw 19th Annual Global Investment Conference. The conference will be held at the Lotte New York Place in New York.
- September 25th – On September 25th at 9:10 am ET, MNKD will be offering a presentation at the Cantor Fitzgerald Global Healthcare Conference. This conference will be held at the InterContinental New York Barclay Hotel in New York.
For both of these presentations, the presenter will be Michael Castagna, MannKind Corporation’s CEO. If you are interested in seeing the presentation, you can access the presentation via live webcast from the News & Events section of the company’s website.
MNKD Is Changing Directions
For some time, after the approval of Afrezza, MNKD fell on hard times. First, the company contracted commercialization to Sanofi, which proved to be the wrong move. Once that contract was terminated, the company had to find a way to sell the inhaled insulin on their own. Unfortunately, this proved to be a tough process.
Nonetheless, it seems as though MNKD is getting through it and starting to perform with flying colors. This is likely the result of advertising that has long been missing. In fact, the company recently launched a television ad that is likely going to help boost sales even more. Now, with a dedicated and well trained sales team, strong advertising materials, and an overwhelmingly strong product offering, MannKind Corporation seems to be taking off.
The Value Proposition
The value proposition with regard to MNKD is a relatively simple one to understand. At the end of the day, the company has created an insulin that can be inhaled rather than injected. That’s a big deal. After all, who likes to give themselves shots? In my opinion, what we’re talking about here is a matter of getting the word out. However, Afrezza isn’t the only point of value for MannKind.
What makes Afrezza possible is the technology that MNKD has created, a technology known as technosphere. This technology makes it so that treatments that could only previously be injected can now be inhaled. This makes the treatment move into the system faster and avoids the use of shots, something that scares a massive amount of people.
Using technosphere, MNKD not only plans on making it so that managing diabetes is easier, the company is working to make other treatments easier to swallow as well. For example, the company has epinephrine in their pipeline. That’s a big story for me. I’m not only scared of needles, but I have a life-threatening allergy to bees.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
At the end of the day, technosphere is an incredible piece of technology. Through this, MNKD has the ability to make managing various ailments a simpler process, and I’m all for simple. On top of that, the company is finally getting things together on the sales side of the coin, making the value proposition an even stronger one. All in all, it looks like MNKD is a great option here, one that you should definitely consider putting on your watch list!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!